ES71
TEAS SECTION 71 RECEIVED
05/22/2026
Back to search
Official data from USPTO
JETEMA THE TOXIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
38
Latest update
05/23/2026
Trademark type
Combined
Nice classes
5
Filing date
04/30/2019
Registration date
08/11/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/11/2020
Last transaction
05/23/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
03
Owner location
KR
Examiner
EINSTEIN, MATTHEW T
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
JETEMA CO., LTD.
Representatives
Kisuk Lee HARNESS, DICKEY & PIERCE, PLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
pharmaceutical agents affecting sensory organs; pharmaceutical agents affecting metabolism; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for urogenital organs; anti-inflammatory and antipyretic preparations; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; ophthalmic preparations; allergy medications; pharmaceutical agents for epidermis; pharmaceutical preparations acting on the central nervous system; analgesics; pharmaceutical preparations for respiratory organs; medicines for dental purposes; Pharmaceutical preparations used in connection with anti-agingfor use in the treatment of glabellar linesfacial wrinklesasymmetries and defects and conditions of the human skinfor facial aesthetic surgeryfacial aesthetic reconstruction; Pharmaceutical preparations for the treatment of neurological disordersmuscle dystoniassmooth muscle disordersautonomic nerve disordersheadacheshyperhydrosissports injuriescerebral palsyspasmstremors and pain; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tractgastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that supportencourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's diseasedementiaAIDS-related dementiaCNSneurological disordersneurodegenerative disordersdepression; neuroprotective agent; antidepressants; pharmaceuticalsantipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism
Publications
History of USPTO decisions and trademark events.
38 publications found
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
08/11/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/19/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/01/2020
FIMP
FINAL DISPOSITION PROCESSED
12/01/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/11/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
08/11/2020
GPNX
NOTIFICATION PROCESSED BY IB
05/29/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/26/2020
PUBO
PUBLISHED FOR OPPOSITION
05/26/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/13/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
05/13/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/06/2020
ALIE
ASSIGNED TO LIE
04/17/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/08/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/07/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/07/2020
RFNT
REFUSAL PROCESSED BY IB
03/27/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/19/2020
GNRT
NON-FINAL ACTION E-MAILED
02/19/2020
CNRT
NON-FINAL ACTION WRITTEN
02/19/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/30/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/29/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/29/2020
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
01/29/2020
RFNT
REFUSAL PROCESSED BY IB
08/23/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/02/2019
RFRR
REFUSAL PROCESSED BY MPU
08/02/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/16/2019
CNRT
NON-FINAL ACTION WRITTEN
07/15/2019
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
07/15/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/12/2019
CNRT
NON-FINAL ACTION WRITTEN
07/11/2019
DOCK
ASSIGNED TO EXAMINER
07/11/2019
MAFR
APPLICATION FILING RECEIPT MAILED
06/22/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/18/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/13/2019
Continuous trademark protection
Get notified about every new filing that threatens JETEMA THE TOXIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.